» Articles » PMID: 24409146

Antidepressant Effects of Ketamine: Mechanisms Underlying Fast-acting Novel Antidepressants

Overview
Journal Front Pharmacol
Date 2014 Jan 11
PMID 24409146
Citations 115
Authors
Affiliations
Soon will be listed here.
Abstract

Newer antidepressants are needed for the many individuals with major depressive disorder (MDD) that do not respond adequately to treatment and because of a delay of weeks before the emergence of therapeutic effects. Recent evidence from clinical trials shows that the NMDA antagonist ketamine is a revolutionary novel antidepressant because it acts rapidly and is effective for treatment-resistant patients. A single infusion of ketamine alleviates depressive symptoms in treatment-resistant depressed patients within hours and these effects may be sustained for up to 2 weeks. Although the discovery of ketamine's effects has reshaped drug discovery for antidepressants, the psychotomimetic properties of this compound limit the use of this therapy to the most severely ill patients. In order to develop additional antidepressants like ketamine, adequate preclinical behavioral screening paradigms for fast-acting antidepressants need to be established and used to identify the underlying neural mechanisms. This review examines the preclinical literature attempting to model the antidepressant-like effects of ketamine. Acute administration of ketamine has produced effects in behavioral screens for antidepressants like the forced swim test, novelty suppression of feeding and in rodent models for depression. Protracted behavioral effects of ketamine have been reported to appear after a single treatment that last for days. This temporal pattern is similar to its clinical effects and may serve as a new animal paradigm for rapid antidepressant effects in humans. In addition, protracted changes in molecules mediating synaptic plasticity have been implicated in mediating the antidepressant-like behavioral effects of ketamine. Current preclinical studies are examining compounds with more specific pharmacological effects at glutamate receptors and synapses in order to develop additional rapidly acting antidepressants without the hallucinogenic side effects or abuse potential of ketamine.

Citing Articles

Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review.

Lima da Cruz R, Leao R, Moulin T Mol Med. 2024; 30(1):244.

PMID: 39701927 PMC: 11657683. DOI: 10.1186/s10020-024-01013-4.


The amino acid metabolism pathway of peripheral T lymphocytes and ketamine-induced schizophrenia-like phenotype.

Wang P, Jiang L, Hu J, Jiang Z, Zhang Y, Chen C J Psychiatry Neurosci. 2024; 49(6):E413-E426.

PMID: 39626901 PMC: 11633891. DOI: 10.1503/jpn-240038.


Simulated synapse loss induces depression-like behaviors in deep reinforcement learning.

Chalmers E, Duarte S, Al-Hejji X, Devoe D, Gruber A, McDonald R Front Comput Neurosci. 2024; 18:1466364.

PMID: 39569353 PMC: 11576168. DOI: 10.3389/fncom.2024.1466364.


Treatment-resistant depression: molecular mechanisms and management.

Kajumba M, Kakooza-Mwesige A, Nakasujja N, Koltai D, Canli T Mol Biomed. 2024; 5(1):43.

PMID: 39414710 PMC: 11485009. DOI: 10.1186/s43556-024-00205-y.


Ketamine's Amelioration of Fear Extinction in Adolescent Male Mice Is Associated with the Activation of the Hippocampal Akt-mTOR-GluA1 Pathway.

Glavonic E, Dragic M, Mitic M, Aleksic M, Lukic I, Ivkovic S Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931336 PMC: 11206546. DOI: 10.3390/ph17060669.


References
1.
Homayoun H, Moghaddam B . NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007; 27(43):11496-500. PMC: 2954603. DOI: 10.1523/JNEUROSCI.2213-07.2007. View

2.
OConnor R, Cryan J . The effects of mGlu₇ receptor modulation in behavioural models sensitive to antidepressant action in two mouse strains. Behav Pharmacol. 2013; 24(2):105-13. DOI: 10.1097/FBP.0b013e32835efc78. View

3.
Lindholm J, Autio H, Vesa L, Antila H, Lindemann L, Hoener M . The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf⁺/⁻ heterozygous null mice. Neuropharmacology. 2011; 62(1):391-7. DOI: 10.1016/j.neuropharm.2011.08.015. View

4.
Monteggia L, Luikart B, Barrot M, Theobold D, Malkovska I, Nef S . Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol Psychiatry. 2006; 61(2):187-97. DOI: 10.1016/j.biopsych.2006.03.021. View

5.
Monteggia L, Gideons E, Kavalali E . The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry. 2012; 73(12):1199-203. PMC: 3574622. DOI: 10.1016/j.biopsych.2012.09.006. View